AbbVie is set to rewrite the timeline of aesthetic medicine, as it received the receipt of a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding the Biologics License Application (BLA) for trenibotulinumtoxinE (TrenibotE).TrenibotE is a potential first-in-class botulinum neurotoxin serotype E designed for facial aesthetics. It is distinguished by a rapid onset of effect (as early as eight hours) and a short duration (two to three weeks), supported by data from 2100 patient’s offering a novel option for patients seeking fast, temporary results.
In the Complete Response Letter , the FDA requested additional information regarding manufacturing processes. Importantly, the letter did not identify any safety or efficacy concerns, nor did it request new clinical trials. AbbVie remains confident in the integrity of its application and intends to submit a comprehensive response to the FDA in the coming months.”We strongly believe trenibotulinumtoxin-E is an important innovation in botulinum toxin science,” said Roopal Thakkar, M.D., executive vice president, R&D, and chief scientific officer at AbbVie. “While we are disappointed by this delay, we are well-positioned to address the agency’s feedback promptly to support the completion of the review.”
Looking ahead, AbbVie views TrenibotE as a strategic cornerstone in the evolution of the aesthetics market. By filling the gap between topical treatments and long-acting neurotoxins, TrenibotE is expected to lower the barrier for “toxin-curious” patients and those seeking precision timing for milestones. Upon addressing the FDA’s manufacturing queries, AbbVie expects to integrate this fast-acting toxin into its world-class Allergan Aesthetics portfolio, further solidifying its leadership in the global neurotoxin market. Regulatory reviews in other international jurisdictions remain on track.
By Pragna Biswas
